Sucampo Pharmaceuticals Inc

Sucampo Pharmaceuticals — Q2 2013 Earnings Presentation

27 slides from Sucampo Pharmaceuticals's earnings presentation, Aug 8, 2013

  1. Slide 1: Second Quarter 2013 Results

    Second Quarter 2013 Results August 8, 2013 ée ? SUCAMPO ‘The Science of Innovation

  2. Slide 2: Corporate Communications

    Corporate Communications e ? SUCAMPO 2 ‘The Science of Innovation

  3. Slide 3: Agenda

    Agenda Highlights of the Quarter Ryuji Ueno, M.D., Ph.D., Ph.D. Commercial Update Stanley G. Miele Pipeline and R&D Update Taryn Joswick Financial Performance Cary J. Claiborne Closing Remarks Ryuji Ueno, M.D., Ph.D., Ph.D. <€ @ SUCAMPO 3 The Science of Innovation

  4. Slide 4: Forward-Looking Statements

    Forward-Looking Statements= product potential, future others, new information, which Sucampo incorporates by reference. e 9 SUCAMPO 4 The Science of Innovation

  5. Slide 5: Ryuji Ueno, M.D., Ph.D., Ph.D.

    Ryuji Ueno, M.D., Ph.D., Ph.D. Chairman, Chief Executive Officer, Chief Scientific Officer, and Co-founder e ? SUCAMPO 5 ‘The Science of Innovation

  6. Slide 6: AMITIZA (lubiprostone) Commercial Highlights

    AMITIZA® (lubiprostone) C United States Japan Europe * FDA approval for opioid * Revenue from Japanese - Actively marketing in induced constipation sales up 49% to ~$3.3M Switzerland (OIC) indication in April this quarter from Q1 eG et q + OIC applications in U.K. progressing for OIC received in Q2

  7. Slide 7: RESCULA (unoprostone isopropyl) Commercial Highlights

    RESCULA® (unoprostoneisopropyi mmercial Highlights United States ¢ Launch activities ongoing - Monthly sales growth <€ @ SUCAMPO 7 The Science of Innovation

  8. Slide 8: Clinical Focus and Stage of Clinical Development

    CLINICAL FOCUS STAGE OF CLINICAL DEVELOPMENT DISCOVERY | PRECLINICAL PHASE 2 PHASE 3 LEAD COMPOUNDS JapaniU.s.* AMITIZA Pediatric Constipation FPFV 2H13 ‘SPI-3608 PO Spinal Stenosis SPI-017 IV Spinal Stenosis. Cobiprostone Oral Mucositis NISUCCESSFULLY COMPLETED I|PROJECTED START BONGOING *Co-develo

  9. Slide 9: Q2 Financial Highlights ($M)

    er Financial Highlights ($M) ™ $19.4 (A $6.9M $14.9 $6.1 Total Operating Net Income Expense YoY YoY $-0.8 Q212 Q2-13 Q213 Q2-12 $ sucAMPo ° The Science of Innovation

  10. Slide 10: Financial Guidance

    Financial Guidance Forecasting approximately break-even in 2013 ¥ Profitability in 2014 Considering ways to share profitability with shareholders in future e 9 SUCAMPO The Science of Innovation

  11. Slide 11: Stanley G. Miele

    | = Stanley G. Miele President, Sucampo Pharma Americas, LLC and SVP, Sales and Marketing e @ SUCAMPO "1 ‘The Science of Innovation

  12. Slide 12: OIC Indication Approved in April 2013

    OIC Indication Approved in April 2013 ° Partner i id-May anesthesiologists since OIC launch Strong AMITIZA YOY Growth * Q2 net sales increase: at YoY to $66.7M * Q2TRx growth: ~3% Yc Increased Awarenes: <€ @ SUCAMPO The Science of Innovation

  13. Slide 13: RESCULA Positive Early Progress

    Positi janifi Positive F ig rogress . % of RESCUL response * 90,000 samples distributed Ongoing Efforts Peer-to-peer i ja sp programs and national and local webinars covered lives * Continue to generate patient trial <€ @ SUCAMPO The Science of Innovation

  14. Slide 14: AMITIZA Global Snapshot

    AMITIZA Global Snapshot Europe Rest of World t vs. Q1 * Over 70% of surveyed discussions cute for Switzerland; Gls writing ANITA. Ad Rxs for CIC. increase AMITIZA prescriptions’ Top reasons for use ot AMITIZA indic: aad ne orieres ctualitlieg 1or Europe, Asia and OIC filings emerging markets Switzer

  15. Slide 15: Taryn Joswick

    Taryn Joswick Vice President, Clinical Development € ? SUCAMPO 15 ‘The Science of Innovation

  16. Slide 16: AMITIZA Clinical Development

    AMITIZA Clinical Developmen P3 pediatri to initiate in 2013 Fe Pp Prog) ° i ‘al .S. alone, close to . i to 6 yrs. i yrs. inclusive « Takeda to fund 70% of developmental costs Developing new liquid dosage form ° provi inici i i i tion for AMITI. * 100% i Takeda Evaluating potential additional LCM opp

  17. Slide 17: Spinal Stenosis: SPI-3608 and SPI-017

    eevee dh eee eS eS (awn \ ToT e= Joe ©) Sea’ Normal Spinal Stor ~=tl SPI-3608 SPI-017 mpleted Pia study * Ongoing P2a trial of SPI-017 (IV) nde ‘iat SPI-3608 (PO) is generally well-tolerated across ae range ° Expect to conclude in 4Q 2013 <€ @ SUCAMPO a The Science of Innovation

  18. Slide 18: Cobiprostone for Oral Mucositis

    Cobiprostone for Oral M Oral mucositis is a severely painful inflammation of the oral cavity in, dry mouth, ulceration Bhi fom Sve suo ne € SUCAMPO 5 (2 Suppl 1):13-21 @ The Science of Innovation

  19. Slide 19: Cary J. Claiborne

    Cary J. Claiborne Chief Financial Officer e ? SUCAMPO 19 ‘The Science of Innovation

  20. Slide 20: Q2 Revenues by Category

    $27.0 $11.7 $12.0 Q2-12 Q2-13 Q2-12 Q2-13 Q2-12 Q2-13 Q2-12 Q2-13 Total Revenues R&D Revenues Product Royalty Product Sales Revenues evenues: $ sucAMPo The Science of Innovation

  21. Slide 21: Net Income ($M)

    let RS ($M) Q212 Q2-13 YTD-12 YTD-13 ¢ @ SUCAMPO The Science of Innovation

  22. Slide 22: Condensed Statements of Operations (Unaudited)

    lated Statements of Operations (Unaudited) Revenue $27.0 $167 62% Cosel gonial 19 oo NA R&D Expense: Higher cost in 2012 eS Ua So associated with phase 3 OIC ED offset by higher ili costs such Expenses: regulatory R&D expense 44 5.2 (16%) 4 G&A Expense: Certain legal matters concluded G&A expense 60

  23. Slide 23: Q2 2013 Financial Highlights

    Q2 2013 Financial Highlights Cash position $93.5M as of June 30, 2013 769 £2013 Pp , + Authorized amount: up to $5M * One class of common stock . y ath 5 ’ Future Guidance * Approxit M ° Profitable in 2014 . i t Le profitability $ sucAMPo The Science of Innovation

  24. Slide 24: Ryuji Ueno, M.D., Ph.D., Ph.D.

    Ryuji Ueno, M.D., Ph.D., Ph.D. Chairman, Chief Executive Officer, Chief Scientific Officer, and Co-founder e ? SUCAMPO 24 ‘The Science of Innovation

  25. Slide 25: Grow sales in Japan in 2013

    Grow sales in Japan in 2013 AMITIZA 2013 Use MHRA sion of CIC and OIC indicati 'U markets via MRP Seek NICE endorsement for d make AMITIZ, available in UK for CIC Launch: Q1 2013 G 1 ane Sate Qa SPI-017 Y completed Qin Progress $sucaMPo ®

  26. Slide 26: ? SUCAMPO

    ¢ ? SUCAMPO 26 ‘The Science of Innovation

  27. Slide 27: References

    References 1. ImpactTrack survey 2013 2. Rajindrajith et al. “Constipation in Children: Novel Insight Into Epidemiology, Pathophysiology and Management.” J Neurogastroenterol Motil. 2014. January; 17(1):35-47. 3. _ Loening-Baucke V. Prevalence rates for constipation and faecal and urinary incontinen

Sucampo Pharmaceuticals — Q2 2013 Earnings Presentation on 6ix